Status:
COMPLETED
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on int...
Eligibility Criteria
Inclusion
- Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening
Exclusion
- Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.
- History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT00140049
Start Date
July 1 2005
End Date
July 1 2006
Last Update
February 18 2021
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Caen, France, 14033
2
Pfizer Investigational Site
Clermont-Ferrand, France, 63003
3
Pfizer Investigational Site
Lyon, France, 69437
4
Pfizer Investigational Site
Marseille, France, 13385